Startup Scout 13 Mar 2020 This Startup Hits Hidden Proteins to Make Cancer Immunotherapies With one foot in Belgium and another in the US, Orionis Biosciences combines US and European talent to develop cancer immunotherapies targeting difficult protein targets. Mission: To fight cancer with two technologies. The first is modifying immune proteins called cytokines to trigger the body to produce specific immune cells against a tumor. The second is […] March 13, 2020 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 12 Mar 2020 Gedea Biotech’s Bacterial Vaginosis Tablet Proves As Good as Antibiotics An antibiotic-free vaginal tablet developed by the Swedish company Gedea Biotech has cured 82% of women of the common vaginal infection bacterial vaginosis in a 24-patient clinical trial. Bacterial vaginosis occurs when the normal vaginal microflora — characterized by a high proportion of bacteria from the genus Lactobacillus — become unbalanced with an overgrowth of […] March 12, 2020 - 3 minutesmins - By Laura Cowen Share WhatsApp Twitter Linkedin Email
Expert Advice 12 Mar 2020 Five Challenges For Life Science Marketers in 2020 Developing a new drug has an estimated cost of €583M to €2.4B. Much of this spending goes towards companies, such as vendors, CROs, and CDMOs, who generate value by commercializing and industrializing innovations to improve the ways researchers study organisms and viruses in the early stages of drug development. For those of us in sales […] March 12, 2020 - 14 minutesmins - By Mark Livingstone Share WhatsApp Twitter Linkedin Email
Expert Advice 11 Mar 2020 Why Women’s Health Can Be a Good Investment Since the Hormone Replacement Therapy market was destroyed almost overnight in 2002 after side effects were reported by researchers, there has been a lot of caution about investing in companies with a focus on women’s health. Mary Kerr, CEO of KaNDy Therapeutics and NeRRe Therapeutics, knows this only too well, but has not let it […] March 11, 2020 - 13 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 11 Mar 2020 Phase III Fail for MedDay’s Multiple Sclerosis Treatment A drug developed by the French company MedDay Pharmaceuticals has failed to treat progressive forms of multiple sclerosis in a phase III trial. The 642 patients recruited into the trial received either a placebo or a high dose of pharmaceutical-grade Biotin, also known as vitamin B₇. The patients had various forms of the autoimmune condition […] March 11, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 11 Mar 2020 Update: Carmat’s Artificial Heart Reaches Two Year Milestone Update (11/03/2020): In a record first, Carmat announced today that one patient in its artificial heart trial has had the device implanted for 2 years. “Passing a two-year period of individual functioning is very encouraging, and confirms the capacity of our device to provide long-term support, which is one of our two key objectives along […] March 11, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 10 Mar 2020 LSP Raises €528M in Largest European Life Sciences Investment Fund Healthcare investor Life Sciences Partners has closed the largest ever European venture capital fund dedicated to new medicines and technologies after raising €528M. LSP 6, the company’s largest private equity fund to date, attracted significantly more than the original €396M target from a diverse investor group that included governments and the EU-supported European Investment Fund. […] March 10, 2020 - 2 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Startup Scout 6 Mar 2020 This Startup Is Developing a DIY Biomarker Diagnostics Kit The Swedish medical device startup Qlife is developing a diagnostic kit that patients can use at home to better control chronic diseases. Mission: To make convenient diagnostics for patients with a home-use kit that they can use to monitor blood biomarkers in chronic conditions such as arthritis. Chronic disorders such as cardiovascular disease and diabetes […] March 6, 2020 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 5 Mar 2020 Drug Development Costs Lower Than Pharma Companies Claim A team of UK and Belgian scientists has reported that drug companies spend up to €1.3B less on drug development than previously suggested, which raises questions about high drug prices set by some biotech and pharma companies. The study, published in the journal JAMA, took publicly available data from pharma company financial reports with the […] March 5, 2020 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 4 Mar 2020 Immunocore Raises €117M to Develop Immunotherapies for Cancer and Hepatitis B UK biotech Immunocore has raised €116.7M in Series B funding to develop drugs that harness the body’s immune cells to fight cancer, viral infections, and autoimmune diseases. This latest funding round for the company, which specializes in redirecting and activating T-cells, includes an international group of new investors led by the US private equity firm […] March 4, 2020 - 2 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 4 Mar 2020 CN Bio Raises €8M to Boost Organ-on-a-Chip Rollout UK cell culture specialist CN Bio Innovations has secured €7.98M (£7M) from Chinese investors to bolster its US market and expand European activities. Investment in the bioengineering company was led by Chinese investor CITIC Securities Company and with further support from existing Hong Kong-based investor CN Innovations Holdings. CN Bio, which creates benchtop instruments to […] March 4, 2020 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 3 Mar 2020 Alnylam Gets Second RNAi Drug Approval from EMA US biotech Alnylam Pharmaceuticals has succeeded in getting its second RNAi drug — for treatment of rare, inherited liver diseases — approved by the European Medicines Authority just months after achieving US FDA approval for the same drug. Alnylam are well known for being pioneers in the RNA interference space. The company achieved the first […] March 3, 2020 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email